CDKN2A and acute myeloid leukemia: Our findings highlight that INK4 proteins are not only differentially expressed among AML subtypes but also contribute to CDK6-targeted therapeutic efficacy.Therefore, they can be considered as predictive indicators of treatment success and guide further strategies.